Tirone Benedetta, Scarabosio Anna, Surico Pier Luigi, Parodi Pier Camillo, D'Esposito Fabiana, Avitabile Alessandro, Foti Caterina, Gagliano Caterina, Zeppieri Marco
Dermatology and Venerology Section, Department of Precision and Regenerative Medicine and Ionan Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy.
Clinic of Plastic and Reconstructive Surgery, Ospedale Santa Maria della Misericordia, 33100 Udine, Italy.
Bioengineering (Basel). 2024 Oct 15;11(10):1029. doi: 10.3390/bioengineering11101029.
Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their applications in treating these malignancies. Additionally, this review addresses the management of ocular and periocular side effects associated with these therapies, emphasizing the importance of a multidisciplinary approach to minimize impact and ensure patient adherence. By integrating current findings and discussing emerging trends, this review aims to highlight the advancements in targeted drug delivery and its potential to improve treatment outcomes and quality of life for patients with periorbital skin malignancies.
靶向药物递送已成为治疗眶周皮肤恶性肿瘤的一种变革性方法，与传统疗法相比，具有提高疗效和减少副作用的潜力。本综述全面概述了眶周恶性肿瘤（包括基底细胞癌、鳞状细胞癌、皮脂腺癌和默克尔细胞癌）的靶向治疗。它探讨了各种靶向治疗（如单克隆抗体、小分子抑制剂和免疫疗法）的作用机制及其在治疗这些恶性肿瘤中的应用。此外，本综述还讨论了与这些疗法相关的眼部和眼周副作用的管理，强调了多学科方法对于最小化影响和确保患者依从性的重要性。通过整合当前研究结果并讨论新趋势，本综述旨在突出靶向药物递送的进展及其改善眶周皮肤恶性肿瘤患者治疗效果和生活质量的潜力。
